INSTRUMENT: FP7-HEALTH-2013-INNOVATION – Project “THINPAD”
TITLE: Targeting the HIV-1 Nucleocpsid Protein to fight Antiretroviral Drug Resistance
The goal of the THINPAD project was to discover and develop novel anti-HIV agents targeting the HIV nucleocapsid protein, which is one of the most conserved sequence within HIV strains and is highly required for HIV replication, being therefore a primary target to overcome antiretroviral drug-resistance.
ViroStatics was one of the 5 partners in the consortium and was supporting the in vitro evaluation of the cytotoxicity profile of the molecules and contributed together with the other SME driving the discovery phase and pre-clinical investigation, favouring the translation of results into innovative applications for health.
Project timeline: Sep 2013-Aug 2016